These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1954 related articles for article (PubMed ID: 33197221)

  • 41. Mechanisms of resistance to immune checkpoint inhibitors.
    Jenkins RW; Barbie DA; Flaherty KT
    Br J Cancer; 2018 Jan; 118(1):9-16. PubMed ID: 29319049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 44. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
    Shergold AL; Millar R; Nibbs RJB
    Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The engineered exosomes targeting ferroptosis: A novel approach to reverse immune checkpoint inhibitors resistance.
    Chen A; Zhang W; Jiang C; Jiang Z; Tang D
    Int J Cancer; 2024 Jul; 155(1):7-18. PubMed ID: 38533694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
    Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
    Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
    Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
    Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
    King GT; Sharma P; Davis SL; Jimeno A
    Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel targets for immune-checkpoint inhibition in cancer.
    Borgeaud M; Sandoval J; Obeid M; Banna G; Michielin O; Addeo A; Friedlaender A
    Cancer Treat Rev; 2023 Nov; 120():102614. PubMed ID: 37603905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events.
    Meybodi SM; Farasati Far B; Pourmolaei A; Baradarbarjastehbaf F; Safaei M; Mohammadkhani N; Samadani AA
    Med Oncol; 2023 Jul; 40(8):243. PubMed ID: 37453930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy.
    Wong SK; Nebhan CA; Johnson DB
    Front Immunol; 2021; 12():786046. PubMed ID: 34868071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological and clinical implications of immune checkpoint blockade in human cancer.
    Kim HD; Park SH
    Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
    Michielin O; Lalani AK; Robert C; Sharma P; Peters S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in primary resistance mechanisms against immune checkpoint inhibitors.
    Li YZ; Zhang HM
    Curr Opin Oncol; 2022 Jan; 34(1):95-106. PubMed ID: 34669646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.